Sign In
Last checked at 
18 Oct 2010 07:00
ο»Ώ
Update on Hikma's US Generics Business
Β
Β
London, 18 October 2010 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ DUBAI: HIK)("Hikma"), the fast growing multinational pharmaceutical group, announces that the dispute between West-Ward Pharmaceutical Corp., Hikma's US agent and wholly-owned subsidiary, and Mutual Pharmaceutical Company, Inc. relating to the sale of oral colchicine tablets has been resolved to the parties' mutual satisfaction. West-Ward has discontinued its sales of oral colchicine until approval of its New Drug Application by the U.S. Food and Drug Administration.
Β
Hikma reconfirms its previously stated guidance of at least 20% revenue growth for its US Generics business for the full year 2010 and continues to expect its core US Generics business to perform well in 2011.
Β
Β
ENDS
Β
Enquiries
Β
|
Hikma Pharmaceuticals PLC |
+44 (0)20 7399 2760 |
|
Susan Ringdal, Investor Relations Director |
|
|
|
|
|
Financial Dynamics |
|
|
Ben Atwell |
+44 (0)20 7269 7242 |
|
Julia Phillips |
+44 (0)20 7269 7187 |
|
Matthew Cole |
|
Β
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing global pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.
Β
Follow the stocks
